Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

<p>Table S7 shows (a) reproducible peaks and (b) GO analysis of ELAVL1-bound transcripts identified in the eCLIP-sequencing data set. The negatively enriched (c) and positively-enriched (d) gene sets identified by GSEA of ELAVL1-bound and differentially expressed transcripts from the RN2c RNA-...

Volledige beschrijving

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Ana Vujovic (15207479) (author)
Andere auteurs:	Laura de Rooij (15207482) (author), Ava Keyvani Chahi (15207485) (author), He Tian Chen (15207488) (author), Brian A. Yee (15207491) (author), Sampath K. Loganathan (15121740) (author), Lina Liu (15207494) (author), Derek C.H. Chan (15207497) (author), Amanda Tajik (15207500) (author), Emily Tsao (15207503) (author), Steven Moreira (14937143) (author), Pratik Joshi (15207506) (author), Joshua Xu (15207509) (author), Nicholas Wong (15207512) (author), Zaldy Balde (15207515) (author), Soheil Jahangiri (15207518) (author), Sasan Zandi (15207521) (author), Stefan Aigner (15207524) (author), John E. Dick (14937554) (author), Mark D. Minden (14961936) (author), Daniel Schramek (15121764) (author), Gene W. Yeo (15207527) (author), Kristin J. Hope (15207530) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors Oncogenes Preclinical Models Xenograft models Small Molecule Agents Stem Cell Biology Cancer stem cells Hematopoiesis
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
door: Amir T. Fathi (15313195)
Gepubliceerd in: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
door: Amir T. Fathi (15313195)
Gepubliceerd in: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
door: Smruthy Sivakumar (15053536)
Gepubliceerd in: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
door: Long Jiang (14956159)
Gepubliceerd in: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
door: Long Jiang (14956159)
Gepubliceerd in: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
door: Long Jiang (14956159)
Gepubliceerd in: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
door: Feng Wang (44414)
Gepubliceerd in: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
door: Feng Wang (44414)
Gepubliceerd in: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
door: Feng Wang (44414)
Gepubliceerd in: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
door: Feng Wang (44414)
Gepubliceerd in: (2025)

Supplementary Tables S3-5 from Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis
door: Nicole Dressel (16918215)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_s171c7if2dos6epvhnrabltquk